KraneShares MSCI All China Health Care Index ETF (KURE) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
P/E 22.68 means the share price is 22.68 times one year of earnings per share. Beta 0.59: the stock has moved about 41% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerKraneShares MSCI All China Health Care Index ETF (KURE) trades at $17.45. KraneShares MSCI All China Health Care Index ETF (KURE) aims to replicate the performance of Chinese healthcare companies. Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for KURE: KURE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
KraneShares MSCI All China Health Care Index ETF (KURE) Financial Services Profile
KraneShares MSCI All China Health Care Index ETF (KURE) provides targeted exposure to the Chinese healthcare sector, tracking an index of free float adjusted market capitalization weighted companies. With a beta of 0.59 and assets under management of $0.08 billion, KURE offers investors a focused investment vehicle within the Chinese equity market.
What Is the Investment Thesis for KURE?
KURE presents a focused investment opportunity in the Chinese healthcare sector, driven by the increasing demand for healthcare services in China. The fund's strategy of mirroring the MSCI All China Health Care Index provides targeted exposure to this growth. Key value drivers include the expansion of China's healthcare infrastructure and increasing healthcare spending. Potential catalysts include regulatory reforms favoring the healthcare sector and advancements in medical technology within China. However, investors may want to evaluate risks such as regulatory changes, geopolitical tensions, and market volatility affecting Chinese equities. With a beta of 0.59, KURE exhibits lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
KURE Key Highlights
The fund invests at least 80% of its net assets in instruments in its underlying index.
- The underlying index is a free float adjusted market capitalization weighted index.
- The fund is designed to measure the equity market performance of Chinese companies in the healthcare sector.
- The fund is non-diversified.
- The fund has a beta of 0.59, indicating lower volatility compared to the market.
Who Are KURE's Competitors?
KURE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALTL Pacer Lunt Large Cap Alternator ETF | $37.96 | -1.26% | $89.1M | — |
| AMID Argent Mid Cap ETF | $34.55 | -2.12% | $118M | — |
| FEBW AllianzIM U.S. Equity Buffer20 Feb ETF | $35.55 | -0.95% | $120M | — |
| GSEU Goldman Sachs ActiveBeta Europe Equity ETF | $46.34 | -1.77% | $115M | — |
| INDS Pacer Industrial Real Estate ETF | $39.11 | -1.07% | $106M | — |
| BLK BlackRock, Inc. | $1169.21 | -0.97% | $181B | 59 5-pillar |
| BX Blackstone Inc. | $115.71 | -0.66% | $143B | 85 5-pillar |
| BAM Brookfield Asset Management | $50.37 | +0.22% | $80.5B | 79 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KURE's Key Strengths?
Targeted exposure to the Chinese healthcare sector.
- Replication of a well-known index (MSCI All China Health Care Index).
- Established brand recognition as a KraneShares ETF.
- Relatively low beta of 0.59.
What Are KURE's Weaknesses?
Non-diversified nature increases risk.
- Concentration in a single country (China) exposes it to geopolitical risks.
- Dependence on the performance of the Chinese healthcare sector.
- Small market cap of $0.08B may limit liquidity.
What Are the Key Risks for KURE?
Rich valuation — a P/E of 22.68 runs well above the Financial Services sector’s ~17.80x, leaving little room for a miss.
- Regulatory changes in China affecting the healthcare sector.
- Geopolitical tensions between China and other countries.
- Economic slowdown in China.
- Competition from other ETFs and investment funds.
What Are KURE's Competitive Advantages?
- Specialized focus on the Chinese healthcare sector.
- Replication of the MSCI All China Health Care Index.
- Established track record in the Chinese equity market.
- Brand recognition as a KraneShares ETF.
What Does KURE Do?
KraneShares MSCI All China Health Care Index ETF (KURE) is designed to provide investors with exposure to the healthcare sector within the Chinese equity market. The fund operates by investing at least 80% of its net assets, plus borrowings for investment purposes, in instruments that mirror its underlying index or possess similar economic characteristics. This underlying index is meticulously constructed as a free float adjusted market capitalization weighted index, adhering to the 10/40 Constraint, which is a diversification rule limiting the weight of any single component. KURE's primary objective is to closely track the equity market performance of Chinese companies operating in the healthcare sector, offering a focused investment tool for those seeking to capitalize on the growth and potential of China's healthcare industry. The fund is non-diversified, meaning it invests a larger percentage of its assets in a smaller number of issuers compared to a diversified fund.
What Products and Services Does KURE Offer?
- Invests in a portfolio of Chinese healthcare companies.
- Tracks the MSCI All China Health Care Index.
- Provides exposure to the Chinese healthcare sector.
- Offers a focused investment vehicle for Chinese equities.
- Replicates the performance of the underlying index.
- Operates as a non-diversified fund.
How Does KURE Make Money?
- Generates revenue through management fees.
- Invests in Chinese healthcare companies.
- Tracks the MSCI All China Health Care Index.
- Provides a vehicle for investors to access the Chinese healthcare market.
What Industry Does KURE Operate In?
KURE operates within the asset management industry, specifically focusing on providing access to the Chinese healthcare sector. The global asset management industry is experiencing growth, driven by increasing demand for specialized investment products. The Chinese healthcare market is expanding due to factors such as an aging population and rising income levels. KURE competes with other ETFs and investment funds offering exposure to Chinese equities and the healthcare sector. Competitors include funds with broader mandates or different weighting methodologies.
Who Are KURE's Key Customers?
- Institutional investors seeking exposure to Chinese healthcare.
- Retail investors interested in the Chinese equity market.
- Financial advisors looking for specialized investment products.
- Pension funds and endowments seeking diversification.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
KURE Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the Chinese healthcare sector.
- Replication of a well-known index (MSCI All China Health Care Index).
- Established brand recognition as a KraneShares ETF.
- Relatively low beta of 0.59.
Bear Case
- Non-diversified nature increases risk.
- Concentration in a single country (China) exposes it to geopolitical risks.
- Dependence on the performance of the Chinese healthcare sector.
- Small market cap of $0.08B may limit liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KURE Latest News
No recent news available for KURE.
KURE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for KURE.
Price Targets
Wall Street price target analysis for KURE.
KURE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for KURE; grades run from A+ (80-100) to F (below 30).
What Investors Ask About KraneShares MSCI All China Health Care Index ETF (KURE) — Financials
What do analysts say about KURE stock?
However, it is important to note that KURE's performance is closely tied to the performance of the Chinese healthcare sector and broader Chinese equity market.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.